Long-term Risk of Malignancy Among Patients Treated With Immunosuppressive Agents for Ocular Inflammation: A Critical Assessment of the Evidence

American Journal of Ophthalmology

Volumn 146, Issue 6, 2008, Pages

  Kempen, John H ^a,b,c   Gangaputra, Sapna ^d   Daniel, Ebenezer ^d   Levy Clarke, Grace A ^f,g   Nussenblatt, Robert B ^g   Rosenbaum, James T ^h   Suhler, Eric B ^h,i   Thorne, Jennifer E ^d,e   Foster, C Stephen ^j,k   Jabs, Douglas A ^d,e,l   Helzlsouer, Kathy J ^e,m  

^a UNIVERSITY OF PENNSYLVANIA   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF PENNSYLVANIA   (United States)

^d JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e JOHNS HOPKINS UNIVERSITY   (United States)

^f St Luke's Cataract and Laser Institute   (United States)

^g NATIONAL EYE INSTITUTE   (United States)

^h OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

ⁱ PORTLAND VA MEDICAL CENTER   (United States)

^j MASSACHUSETTS EYE RESEARCH AND SURGERY INSTITUTION   (United States)

^k HARVARD MEDICAL SCHOOL   (United States)

^l MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^m MERCY MEDICAL CENTER   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ADALIMUMAB; ALKYLATING AGENT; AZATHIOPRINE; CALCINEURIN INHIBITOR; CHLORAMBUCIL; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DACLIZUMAB; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; TACROLIMUS;

ARTICLE; BLADDER CANCER; CANCER RISK; CARCINOGENESIS; DIGESTIVE SYSTEM CANCER; DISEASE SEVERITY; DRUG MEGADOSE; DRUG SUBSTITUTION; DRUG WITHDRAWAL; EYE INFLAMMATION; GENOTOXICITY; HEMATOLOGIC MALIGNANCY; HUMAN; HYDRATION; IMMUNE DEFICIENCY; LEUKEMIA; LYMPHOMA; POSTTRANSPLANT LYMPHOPROLIFERATIVE DISEASE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS; SIDE EFFECT; SKIN CANCER; SKIN CARCINOMA; SQUAMOUS CELL CARCINOMA; SUN EXPOSURE; TREATMENT DURATION;

EID: 56249109045     PISSN: 00029394     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ajo.2008.04.035     Document Type: Article

References (96)

1. Gordon D.M. Prednisone and prednisolone in ocular disease. Am J Ophthalmol 41 (1956) 593-600
2. Jabs D.A., Rosenbaum J.T., Foster C.S., et al. Guidelines for the use of immunosuppressive drugs in patients with ocular inflammatory disorders: recommendations of an expert panel. Am J Ophthalmol 130 (2000) 492-513
3. Lindelof B., Sigurgeirsson B., Gabel H., and Stern R.S. Incidence of skin cancer in 5,356 patients following organ transplantation. Br J Dermatol 143 (2000) 513-519
4. Hartevelt M.M., Bavinck J.N., Kootte A.M., Vermeer B.J., and Vandenbroucke J.P. Incidence of skin cancer after renal transplantation in The Netherlands. Transplantation 49 (1990) 506-509
5. McGregor J.M., Berkhout R.J., Rozycka M., et al. p53 mutations implicate sunlight in post-transplant skin cancer irrespective of human papillomavirus status. Oncogene 15 (1997) 1737-1740
6. Iftner A., Klug S.J., Garbe C., et al. The prevalence of human papillomavirus genotypes in nonmelanoma skin cancers of nonimmunosuppressed individuals identifies high-risk genital types as possible risk factors. Cancer Res 63 (2003) 7515-7519
7. Blohme I., and Larko O. Skin lesions in renal transplant patients after 10 to 23 years of immunosuppressive therapy. Acta Derm Venereol 70 (1990) 491-494
8. Snow A.L., and Martinez O.M. Epstein-Barr virus: evasive maneuvers in the development of PTLD. Am J Transplant 7 (2007) 271-277
9. Preiksaitis J.K., and Keay S. Diagnosis and management of posttransplant lymphoproliferative disorder in solid-organ transplant recipients. Clin Infect Dis 33 (2001) S38-S46
10. Starzl T.E., Nalesnik M.A., Porter K.A., et al. Reversibility of lymphomas and lymphoproliferative lesions developing under cyclosporin-steroid therapy. Lancet 323 (1984) 583-587
11. Salloum E., Cooper D.L., Howe G., et al. Spontaneous regression of lymphoproliferative disorders in patients treated with methotrexate for rheumatoid arthritis and other rheumatic diseases. J Clin Oncol 14 (1996) 1943-1949
12. Swinnen L.J., Mullen G.M., Carr T.J., Costanzo M.R., and Fisher R.I. Aggressive treatment for postcardiac transplant lymphoproliferation. Blood 86 (1995) 3333-3340
13. Birkeland S.A., and Hamilton-Dutoit S. Is posttransplant lymphoproliferative disorder (PTLD) caused by any specific immunosuppressive drug or by the transplantation per se?. Transplantation 76 (2003) 984-988
14. Hunt S.A. Malignancy in organ transplantation: heart. Transplant Proc 34 (2002) 1874-1876
15. Penn I. The effect of immunosuppression on pre-existing cancers. Transplantation 55 (1993) 742-747
16. Pedersen-Bjergaard J., Ersboll J., Hansen V.L., et al. Carcinoma of the urinary bladder after treatment with cyclophosphamide for non-Hodgkin's lymphoma. N Engl J Med 318 (1988) 1028-1032
17. Radis C.D., Kahl L.E., Baker G.L., et al. Effects of cyclophosphamide on the development of malignancy and on long-term survival of patients with rheumatoid arthritis. A 20-year follow-up study. Arthritis Rheum 38 (1995) 1120-1127
18. Fairchild W.V., Spence C.R., Solomon H.D., and Gangai M.P. The incidence of bladder cancer after cyclophosphamide therapy. J Urol 122 (1979) 163-164
19. Hoffman G.S., Kerr G.S., Leavitt R.Y., et al. Wegener granulomatosis: an analysis of 158 patients. Ann Intern Med 116 (1992) 488-498
20. Puri H.C., and Campbell R.A. Cyclophosphamide and malignancy. Lancet 309 (1977) 1306
21. Tucker M.A., Meadows A.T., Boice Jr. J.D., et al. Leukemia after therapy with alkylating agents for childhood cancer. J Natl Cancer Inst 78 (1987) 459-464
22. Baker G.L., Kahl L.E., Zee B.C., Stolzer B.L., Agarwal A.K., and Medsger Jr. T.A. Malignancy following treatment of rheumatoid arthritis with cyclophosphamide. Long-term case-control follow-up study. Am J Med 83 (1987) 1-9
23. Baltus J.A., Boersma J.W., Hartman A.P., and Vandenbroucke J.P. The occurrence of malignancies in patients with rheumatoid arthritis treated with cyclophosphamide: a controlled retrospective follow-up. Ann Rheum Dis 42 (1983) 368-373
24. Travis L.B., Curtis R.E., Glimelius B., et al. Bladder and kidney cancer following cyclophosphamide therapy for non-Hodgkin's lymphoma. J Natl Cancer Inst 87 (1995) 524-530
25. Schmahl D., Habs M., and Tacchi A.M. Prevention of tumor formation in the bladder by sodium-2-mercaptoethane sulfonate (mesna). Experimental studies and clinical consequences. Urologe A 23 (1984) 291-296
26. Chabner B.A. Second neoplasm-a complication of cancer chemotherapy. N Engl J Med 297 (1977) 213-215
27. Talar-Williams C., Hijazi Y.M., Walther M.M., et al. Cyclophosphamide-induced cystitis and bladder cancer in patients with Wegener granulomatosis. Ann Intern Med 124 (1996) 477-484
28. Shepherd J.D., Pringle L.E., Barnett M.J., Klingemann H.G., Reece D.E., and Phillips G.L. Mesna versus hyperhydration for the prevention of cyclophosphamide-induced hemorrhagic cystitis in bone marrow transplantation. J Clin Oncol 9 (1991) 2016-2020
29. Patapanian H., Graham S., Sambrook P.N., et al. The oncogenicity of chlorambucil in rheumatoid arthritis. Br J Rheumatol 27 (1988) 44-47
30. Lerner H.J. Acute myelogenous leukemia in patients receiving chlorambucil as long-term adjuvant chemotherapy for stage II breast cancer. Cancer Treat Rep 62 (1978) 1135-1138
31. Boivin J.F., Hutchison G.B., Zauber A.G., et al. Incidence of second cancers in patients treated for Hodgkin's disease. J Natl Cancer Inst 87 (1995) 732-741
32. Berk P.D., Goldberg J.D., Silverstein M.N., et al. Increased incidence of acute leukemia in polycythemia vera associated with chlorambucil therapy. N Engl J Med 304 (1981) 441-447
33. Hojo M., Morimoto T., Maluccio M., et al. Cyclosporine induces cancer progression by a cell-autonomous mechanism. Nature 397 (1999) 530-534
34. York L.J., and Qualtiere L.F. Cyclosporin abrogates virus-specific T-cell control of EBV-induced B-cell lymphoproliferation. Viral Immunol 3 (1990) 127-136
35. Birkeland S.A., Bendtzen K., Moller B., Hamilton-Dutoit S., and Andersen H.K. Interleukin-10 and posttransplant lymphoproliferative disorder after kidney transplantation. Transplantation 67 (1999) 876-881
36. Palanduz S., Sever M.S., Ozturk S., et al. Genotoxic potential of cyclosporin A in patients with renal transplantation. Cell Biol Toxicol 15 (1999) 13-17
37. Yuzawa K., Kondo I., Fukao K., Iwasaki Y., and Hamaguchi H. Mutagenicity of cyclosporine. Induction of sister chromatid exchange in human cells. Transplantation 42 (1986) 61-63
38. Zwanenburg T.S., Suter W., and Matter B.E. Absence of genotoxic potential for cyclosporine in experimental systems. Transplant Proc 20 (1988) 931-933
39. Dantal J., Hourmant M., Cantarovich D., et al. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 351 (1998) 623-628
40. McGeown M.G., Douglas J.F., and Middleton D. One thousand renal transplants at Belfast City Hospital: post-graft neoplasia 1968-1999, comparing azathioprine only with cyclosporin-based regimes in a single center. Clin Transpl (2000) 193-202
41. Van den Borne B.E., Landewe R.B., Houkes I., et al. No increased risk of malignancies and mortality in cyclosporin A-treated patients with rheumatoid arthritis. Arthritis Rheum 41 (1998) 1930-1937
42. Paul C.F., Ho V.C., McGeown C., et al. Risk of malignancies in psoriasis patients treated with cyclosporine: a 5-year cohort study. J Invest Dermatol 120 (2003) 211-216
43. Caillard S., Dharnidharka V., Agodoa L., Bohen E., and Abbott K. Posttransplant lymphoproliferative disorders after renal transplantation in the United States in era of modern immunosuppression. Transplantation 80 (2005) 1233-1243
44. Opelz G., and Dohler B. Lymphomas after solid organ transplantation: a collaborative transplant study report. Am J Transplant 4 (2004) 222-230
45. Dharnidharka V.R., Sullivan E.K., Stablein D.M., Tejani A.H., and Harmon W.E. Risk factors for posttransplant lymphoproliferative disorder (PTLD) in pediatric kidney transplantation: a report of the North American Pediatric Renal Transplant Cooperative Study (NAPRTCS). Transplantation 71 (2001) 1065-1068
46. Younes B.S., McDiarmid S.V., Martin M.G., et al. The effect of immunosuppression on posttransplant lymphoproliferative disease in pediatric liver transplant patients. Transplantation 70 (2000) 94-99
47. Mithoefer A.B., Supran S., and Freeman R.B. Risk factors associated with the development of skin cancer after liver transplantation. Liver Transpl 8 (2002) 939-944
48. Frezza E.E., Fung J.J., and van Thiel D.H. Non-lymphoid cancer after liver transplantation. Hepatogastroenterology 44 (1997) 1172-1181
49. Jonas S., Rayes N., Neumann U., et al. De novo malignancies after liver transplantation using tacrolimus-based protocols or cyclosporine-based quadruple immunosuppression with an interleukin-2 receptor antibody or antithymocyte globulin. Cancer 80 (1997) 1141-1150
50. Yakupoglu Y.K., Buell J.F., Woodle S., and Kahan B.D. Individualization of immunosuppressive therapy. III. Sirolimus associated with a reduced incidence of malignancy. Transplant Proc 38 (2006) 358-361
51. Huang S., and Houghton P.J. Inhibitors of mammalian target of rapamycin as novel antitumor agents: from bench to clinic. Curr Opin Investig Drugs 3 (2002) 295-304
52. Brenneisen P., Wenk J., Wlaschek M., Krieg T., and Scharffetter-Kochanek K. Activation of p70 ribosomal protein S6 kinase is an essential step in the DNA damage-dependent signaling pathway responsible for the ultraviolet B-mediated increase in interstitial collagenase (MMP-1) and stromelysin-1 (MMP-3) protein levels in human dermal fibroblasts. J Biol Chem 275 (2000) 4336-4344
53. Mathew T., Kreis H., and Friend P. Two-year incidence of malignancy in sirolimus-treated renal transplant recipients: results from five multicenter studies. Clin Transplant 18 (2004) 446-449
54. Connell W.R., Kamm M.A., Dickson M., Balkwill A.M., Ritchie J.K., and Lennard-Jones J.E. Long-term neoplasia risk after azathioprine treatment in inflammatory bowel disease. Lancet 343 (1994) 1249-1252
55. Singh G., Fries J.F., Spitz P., and Williams C.A. Toxic effects of azathioprine in rheumatoid arthritis. A national post-marketing perspective. Arthritis Rheum 32 (1989) 837-843
56. Castor C.W., and Bull F.E. Review of United States data on neoplasms in rheumatoid arthritis. Am J Med 78 (1985) 33-38
57. Fraser A.G., Orchard T.R., Robinson E.M., and Jewell D.P. Long-term risk of malignancy after treatment of inflammatory bowel disease with azathioprine. Aliment Pharmacol Ther 16 (2002) 1225-1232
58. Hazleman B.L. The comparative incidence of malignant disease in rheumatoid arthritics exposed to different treatment regimens. Ann Rheum Dis 41 (1982) 12-17
59. Confavreux C., Saddier P., Grimaud J., Moreau T., Adeleine P., and Aimard G. Risk of cancer from azathioprine therapy in multiple sclerosis: a case-control study. Neurology 46 (1996) 1607-1612
60. Kwon J.H., and Farrell R.J. The risk of lymphoma in the treatment of inflammatory bowel disease with immunosuppressive agents. Crit Rev Oncol Hematol 56 (2005) 169-178
61. Jensen P., Moller B., and Hansen S. Skin cancer in kidney and heart transplant recipients and different long-term immunosuppressive therapy regimens. J Am Acad Dermatol 42 (2000) 307
62. Bailin P.L., Tindall J.P., Roenigk Jr. H.H., and Hogan M.D. Is methotrexate therapy for psoriasis carcinogenic?. A modified retrospective-prospective analysis. JAMA 232 (1975) 359-362
63. Nyfors A., and Jensen H. Frequency of malignant neoplasms in 248 long-term methotrexate-treated psoriatics. A preliminary study. Dermatologica 167 (1983) 260-261
64. Rustin G.J., Newlands E.S., Lutz J.M., et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 14 (1996) 2769-2773
65. Alarcon G.S., Tracy I.C., Strand G.M., Singh K., and Macaluso M. Survival and drug discontinuation analyses in a large cohort of methotrexate treated rheumatoid arthritis patients. Ann Rheum Dis 54 (1995) 708-712
66. Tishler M., Caspi D., and Yaron M. Long-term experience with low-dose methotrexate in rheumatoid arthritis. Rheumatol Int 13 (1993) 103-106
67. Georgescu L., Quinn G.C., Schwartzman S., and Paget S.A. Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment. Semin Arthritis Rheum 26 (1997) 794-804
68. Wolfe F., and Michaud K. The effect of methotrexate and anti-tumor necrosis factor therapy on the risk of lymphoma in rheumatoid arthritis in 19,562 patients during 89,710 person-years of observation. Arthritis Rheum 56 (2007) 1433-1439
69. O'Neill J.O., Edwards L.B., and Taylor D.O. Mycophenolate mofetil and risk of developing malignancy after orthotopic heart transplantation: analysis of the transplant registry of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 25 (2006) 1186-1191
70. David K.M., Morris J.A., Steffen B.J., Chi-Burris K.S., Gotz V.P., and Gordon R.D. Mycophenolate mofetil vs. azathioprine is associated with decreased acute rejection, late acute rejection, and risk for cardiovascular death in renal transplant recipients with pre-transplant diabetes. Clin Transplant 19 (2005) 279-285
71. Wang K., Zhang H., Li Y., et al. Safety of mycophenolate mofetil versus azathioprine in renal transplantation: a systematic review. Transplant Proc 36 (2004) 2068-2070
72. Leckel K., Beecken W.D., Jonas D., et al. The immunosuppressive drug mycophenolate mofetil impairs the adhesion capacity of gastrointestinal tumour cells. Clin Exp Immunol 134 (2003) 238-245
73. Engl T., Makarevic J., Relja B., et al. Mycophenolate mofetil modulates adhesion receptors of the beta1 integrin family on tumor cells: impact on tumor recurrence and malignancy. BMC Cancer 5 (2005) 4
74. Vegso G., Sebestyen A., Paku S., et al. Antiproliferative and apoptotic effects of mycophenolic acid in human B-cell non-Hodgkin lymphomas. Leuk Res 31 (2007) 1003-1008
75. Bongartz T., Sutton A.J., Sweeting M.J., Buchan I., Matteson E.L., and Montori V. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 295 (2006) 2275-2285
76. Bongartz T., Matteson E.L., Montori V.M., Sutton A.J., Sweeting M., and Buchan I. Author reply: Anti-TNF Antibody Therapy in Rheumatoid Arthritis and the Risk of Serious Infections and Malignancies. JAMA 296 (2006) 2203-2204
77. Okada S.K., and Siegel J.N. Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis. JAMA 296 (2006) 2201-2202
78. Stone J.H., Holbrook J.T., Marriott M.A., et al. Solid malignancies among patients in the Wegener's Granulomatosis Etanercept Trial. Arthritis Rheum 54 (2006) 1608-1618
79. Setoguchi S., Solomon D.H., Weinblatt M.E., et al. Tumor necrosis factor alpha antagonist use and cancer in patients with rheumatoid arthritis. Arthritis Rheum 54 (2006) 2757-2764
80. Fleischmann R.M., Tesser J., Schiff M.H., et al. Safety of extended treatment with anakinra in patients with rheumatoid arthritis. Ann Rheum Dis 65 (2006) 1006-1012
81. Lebwohl M., Blum R., Berkowitz E., et al. No evidence for increased risk of cutaneous squamous cell carcinoma in patients with rheumatoid arthritis receiving etanercept for up to 5 years. Arch Dermatol 141 (2005) 861-864
82. Jacobsson L.T., Turesson C., Nilsson J.A., et al. Treatment with TNF blockers and mortality risk in patients with rheumatoid arthritis. Ann Rheum Dis 66 (2007) 670-675
83. Askling J., Fored C.M., Brandt L., et al. Risks of solid cancers in patients with rheumatoid arthritis and after treatment with tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1421-1426
84. Askling J., Fored C.M., Baecklund E., et al. Haematopoietic malignancies in rheumatoid arthritis: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists. Ann Rheum Dis 64 (2005) 1414-1420
85. Wolfe F., and Michaud K. Biologic treatment of rheumatoid arthritis and the risk of malignancy: analyses from a large US observational study. Arthritis Rheum 56 (2007) 2886-2895
86. Carmona L., Descalzo M.A., Perez-Pampin E., et al. All-cause and cause-specific mortality in rheumatoid arthritis are not greater than expected when treated with tumour necrosis factor antagonists. Ann Rheum Dis 66 (2007) 880-885
87. Geborek P., Bladstrom A., Turesson C., et al. Tumour necrosis factor blockers do not increase overall tumour risk in patients with rheumatoid arthritis, but may be associated with an increased risk of lymphomas. Ann Rheum Dis 64 (2005) 699-703
88. Biancone L., Orlando A., Kohn A., et al. Infliximab and newly diagnosed neoplasia in Crohn's disease: a multicentre matched pair study. Gut 55 (2006) 228-233
89. Webster A.C., Playford E.G., Higgins G., Chapman J.R., and Craig J.C. Interleukin 2 receptor antagonists for renal transplant recipients: a meta-analysis of randomized trials. Transplantation 77 (2004) 166-176
90. Waldmann T.A. Daclizumab (anti-Tac, Zenapax) in the treatment of leukemia/lymphoma. Oncogene 26 (2007) 3699-3703
91. Lane L., Tamesis R., Rodriguez A., et al. Systemic immunosuppressive therapy and the occurrence of malignancy in patients with ocular inflammatory disease. Ophthalmology 102 (1995) 1530-1535
92. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 340 (1999) 115-126
93. Beauparlant P., Papp K., and Haraoui B. The incidence of cancer associated with the treatment of rheumatoid arthritis. Semin Arthritis Rheum 29 (1999) 148-158
94. Harper D.M., Franco E.L., Wheeler C.M., et al. Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial. Lancet 367 (2006) 1247-1255
95. Wolfe F., and Michaud K. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients. Arthritis Rheum 50 (2004) 1740-1751
96. Choi H.K., Hernan M.A., Seeger J.D., Robins J.M., and Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet 359 (2002) 1173-1177